Abstract
This study aims to compare the risks of cancer among patients with type 2 diabetes mellitus (T2DM) on metformin-sulfonylurea dual therapy intensified with dipeptidyl peptidase 4 inhibitors (DPP4i), thiazolidinediones, or insulin. We assembled a retrospective cohort data of 20 577 patients who were free of cancer and on metformin-sulfonylurea dual therapy, and whose drug treatments were intensified with DPP4i (n=9957), insulin (n=7760), or thiazolidinediones (n=2860) from January 2006 to December 2017. Propensity-score weighting was used to balance out baseline covariates across the three groups. HRs for any types of cancer, cancer mortality, and all-cause mortality were assessed using Cox proportional-hazards models. Over a mean follow-up period of 34 months with 58 539 person-years, cumulative incidences of cancer, cancer mortality, and all-cause mortality were 0.028, 0.009, and 0.072, respectively. Patients intensified with insulin had the highest incidence of all-cause mortality (incidence rate=3.22/100 person-years) and the insulin itself posed the greatest risk (HR 2.46, 95% CI 2.25 to 2.70, p<0.001; 2.44, 95% CI 2.23 to 2.67) compared with thiazolidinediones and DPP4i, respectively. Comparing between thiazolidinediones an...Continue Reading
References
Jul 20, 2001·Medical Hypotheses·M F McCarty
Oct 14, 2004·Gastroenterology·Yu-Xiao YangJames D Lewis
Jul 1, 2009·BMJ : British Medical Journal·Jonathan A C SterneJames R Carpenter
Aug 6, 2011·Multivariate Behavioral Research·Peter C Austin
Apr 25, 2012·Cancer Causes & Control : CCC·Adedayo A OnitiloSuhail A Doi
Jun 2, 2012·BMJ : British Medical Journal·Laurent AzoulaySamy Suissa
Aug 11, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Patricia WongYu-Xiao Yang
Nov 23, 2012·Diabetes Care·Samy Suissa, Laurent Azoulay
Feb 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Craig J CurrieChristopher Ll Morgan
May 7, 2013·Diabetes Care·Peter C ButlerEdwin A M Gale
Jul 16, 2013·Acta Diabetologica·Matteo MonamiEdoardo Mannucci
Jun 16, 2015·Scientific Reports·Lang WuMohammad Hassan Murad
Oct 21, 2015·Statistics in Medicine·Ariel LindenJohn L Adams
Dec 3, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gadi ShlomaiEmily Jane Gallagher
Mar 10, 2017·Expert Opinion on Pharmacotherapy·André J Scheen
Jun 3, 2017·Statistical Methods in Medical Research·Clémence LeyratElizabeth J Williamson
Jul 12, 2017·Annals of Internal Medicine·Tyler J VanderWeele, Peng Ding
Aug 16, 2017·Scientific Reports·Ming ZhaoShizhong Bu
Sep 6, 2017·BJU International·Roger LiAshish M Kamat
Nov 18, 2017·Diabetes Research and Clinical Practice·Mayer B Davidson, Deyu Pan
Nov 28, 2017·Scientific Reports·Ming ZhaoShizhong Bu
Dec 3, 2017·The Lancet. Diabetes & Endocrinology·Yikyung Park, Graham A Colditz
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Mar 25, 2018·Diabetes/metabolism Research and Reviews·Jetty A OverbeekGiel Nijpels
Jun 19, 2018·Epidemiology·Maya B MathurTyler J VanderWeele
Oct 7, 2018·Diabetes Care·Melanie J DaviesJohn B Buse
Dec 7, 2018·BMJ : British Medical Journal·Devin AbrahamiLaurent Azoulay
Dec 19, 2018·Diabetes Care·UNKNOWN American Diabetes Association
Jan 15, 2019·Annals of Internal Medicine·Calvin KeAndrea Luk
Jan 25, 2019·JAMA : the Journal of the American Medical Association·Sebastien HaneuseDavid Arterburn
May 8, 2019·Diabetes, Obesity & Metabolism·Katsiaryna BykovElisabetta Patorno
Dec 27, 2019·PLoS Medicine·Carlos K H WongCindy L K Lam